-
-

 
-
Nov 1 2022
Recent article published in Molecular Oncology with MedRod® implants i...

-


PRICE QUOTE AND TECHNICAL INQUIRIES

Request Information


FOLLOW US

Letrozole

For mice and rats in metabolic studies, breast and prostate cancer xenograft, PDX and syngeneic studies and studies related to aromatase inhibitors

Letrozole (LTZ) implants for preclinical in vivo studies.
Drug release: At least 100 days, specific implants up to 6 months
Dose range: 5 µg – 75 µg/day

-
About Us
 
-
 Management
-
 History
-
Implant Technology
 
-
 E1
-
 E2
-
 DHT
-
 P4
-
 TE
-
 LTZ
-
Drug Delivery Solutions
 
-
 Feasibility study of novel compound
-
Services
 
References
 
-
 MedRod brochure
-
Contact Us
 
Benefits of MedRod®
 
128116  | Copyright © 2023 PreclinApps Ltd   
Web dev. Webbinen.net